Stock Spotlight: Nanosonics Ltd (ASX:NAN)

About Nanosonics

Nanosonics Limited operates as an infection prevention company globally. The company manufactures and distributes the trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. Its product portfolio includes trophon2 that provides protection across various level disinfection HLD cycle; AuditPro nanosonics, an infection control workflow compliance management; Trophon EPR, a patented sonicated mist technology that provides high level disinfection of both endocavitary and surface ultrasound probes; and CORIS, an instrument reprocessing product platform. The company was incorporated in 2000 and is headquartered in Macquarie Park, Australia.

Key Stats

Source: Yahoo Finance. Data as of 05/08/25.

Growth Potential

• Requirement for ultrasound disinfection. Ultrasound transducers must be disinfected between patients to prevent cross-infection. Trophon EPR is a significant improvement above traditional methods (soak, spray, wipe or other manual reprocessing/disinfection method). For instance, traditional soaking takes ~25 minutes versus Trophon which takes ~7-8 minutes to disinfect ultrasound probes.
• Potential addressable installed base of ~120,000 Trophon EPR units globally (~40,000 in the US, Europe and Rest of World each).
• New guidelines and regulation drive pathways to reinforce requirements for high level disinfection. For instance, new guidelines in Australia and New Zealand setting Trophon as the standard in high level disinfection.
• Continued growth in North America to be driven by its direct sales team with adoption remaining strong and Trophon becoming the standard of care.
• CORIS launch in FY26 could potentially exceed market expectations
• Large and credible distribution partner is retained in GE Healthcare with demand for safety inventory.
• Managed Equipment Service business model (MES) in the UK overcoming capital budget constraints by clients.
•  Progress with geographic expansion.
• Strong balance sheet to support growth strategy
  
  

Key Risks

• Competitive pressures as potential entrants enter the market.
• Non-receptive markets where NAN’s product is considered overkill compared to traditional disinfection methods such as using sterilized wipes.
• CORIS launch in FY26 disappoints relative to expectations.
• Key customer risk as one customer is NAN’s largest customer.
• Product faults or incidents where recalls are required.
• Adverse foreign currency movements in AUD/USD.
• Poor execution of R&D with no progress.
• Nature of business makes it prone to easily reaching a natural penetration rate, where growth becomes subdued.